Barclays PLC Boosts Stock Position in INmune Bio, Inc. (NASDAQ:INMB)

Barclays PLC lifted its holdings in shares of INmune Bio, Inc. (NASDAQ:INMB) by 601.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 29,044 shares of the company’s stock after buying an additional 24,906 shares during the period. Barclays PLC owned about 0.13% of INmune Bio worth $157,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of INMB. Financial Advocates Investment Management grew its holdings in INmune Bio by 17.4% during the 3rd quarter. Financial Advocates Investment Management now owns 13,500 shares of the company’s stock valued at $73,000 after buying an additional 2,000 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of INmune Bio during the third quarter worth $79,000. Rhumbline Advisers acquired a new stake in shares of INmune Bio during the second quarter worth $121,000. Fermata Advisors LLC boosted its holdings in INmune Bio by 25.2% in the third quarter. Fermata Advisors LLC now owns 42,730 shares of the company’s stock valued at $230,000 after acquiring an additional 8,590 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of INmune Bio during the 3rd quarter worth about $249,000. 12.72% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Alliance Global Partners initiated coverage on INmune Bio in a research report on Monday, October 21st. They issued a “buy” rating and a $20.00 price objective on the stock. Raymond James began coverage on INmune Bio in a research note on Friday, September 27th. They set an “outperform” rating and a $18.00 price objective for the company.

INmune Bio Stock Up 17.5 %

INMB opened at $7.67 on Thursday. The business has a fifty day simple moving average of $5.20 and a 200-day simple moving average of $6.06. The firm has a market cap of $170.06 million, a PE ratio of -3.52 and a beta of 1.78. INmune Bio, Inc. has a fifty-two week low of $4.32 and a fifty-two week high of $14.74.

INmune Bio (NASDAQ:INMB) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.11). During the same quarter in the previous year, the business posted ($0.48) EPS. On average, equities research analysts anticipate that INmune Bio, Inc. will post -2.24 EPS for the current fiscal year.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.